IPAM
REGN icon

Investment Partners Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Investment Partners Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-297
Closed -$229K – 177
2026
Q1 		$229K Buy
+297
New +$227K 0.14% 149

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MCI
McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
BS
Banco Santander Madrid, Spain $16.1B AUM 35.02% 1-Year Est. Return

Investment Partners Asset Management's REGN Position: Q2 2026 in Review

Investment Partners Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 297 shares — an estimated $229K sold.

Investment Partners Asset Management first reported a position in REGN in Q1 2026 and held it in 1 quarter. The position peaked at $229K in Q1 2026. 418 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Investment Partners Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Investment Partners Asset Management sold 297 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $229K.
  • Investment Partners Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Investment Partners Asset Management's Regeneron Pharmaceuticals position peaked at $229K in Q1 2026.
  • 418 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Investment Partners Asset Management's 13F filing for Q2 2026, filed 24 Jul 2026.